 This study found that the comprehensive economic and trade agreement between Canada and the European Union has had a positive impact on the development time of prescription drugs in Canada. Specifically, it has extended the patent protection period for certain drugs by two years, which can help compensate pharmaceutical companies for their investment in research and development. However, this benefit may only apply to biological drugs, as opposed to small molecule drugs. Additionally, the study found that the patent term extension did not significantly affect the overall development time of drugs, suggesting that the benefits of the agreement may be limited. This article was authored by Joel Lexton.